Paul R. A. Stokes

Paul R. A. Stokes

Auto-generated profile, based on publicly available information

Paul R. A. Stokes

Department of Psychological Medicine Institute of Psychiatry, Psychology and Neuroscience, King's College London London UK

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2015 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
DNDavid J. Nutt
David J. Nutt
ALAnne Lingford-Hughes
Anne Lingford-Hughes
DEDavid Erritzoe
David Erritzoe
PSPaul R. A. Stokes
Paul R. A. Stokes

1 August 2009 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
OHO. D. Howes
O. D. Howes
AEA. Egerton
A. Egerton
VAV. Allan
V. Allan
PMP. McGuire
P. McGuire
PSP. Stokes
P. Stokes
SKS. Kapur
S. Kapur
Molecular imaging studies have generated important in vivo insights into the etiology of schizophrenia and treatment response. This article first reviews the PET and SPECT evidence implicating dopaminergic dysfunction, especially presynaptic dysregulation, as a mechanism for psychosis. Second, it summarises the neurochemical imaging studies of antipsychotic action, focussing on D2/3 receptors. These studies show that all currently licensed antipsychotic drugs block striatal D2/3 receptors in vivo- a site downstream of the likely principal dopaminergic pathophysiology in schizophrenia- and that D2/3 occupancy above a threshold is required for antipsychotic treatment response. However, adverse events, such as extra-pyramidal side-effects or hyperprolactinemia, become much more likely at higher occupancy levels, which indicates there is an optimal ‘therapeutic window‘ for D2/3 occupancy, and questions the use of high doses of antipsychotic treatment in clinical practice and trials. Adequate D2/3 blockade by antipsychotic drugs is necessary but not always sufficient for antipsychotic response. Molecular imaging studies of clozapine, the one antipsychotic licensed for treatment resistant schizophrenia, have provided insights into the mechanisms underlying its unique efficacy. To link this pharmacology to the phenomenology of the illness, we discuss the role of dopamine in motivational salience and show how i) psychosis could be viewed as a process of aberrant salience, and ii) antipsychotics might provide symptomatic relief by blocking this aberrant salience. Finally, we discuss the implications of these PET and SPECT findings for new avenues of drug development.

1 October 2012 in NeuroImage
Verified
Journal Article
Open access
LCLuke Clark
Luke Clark
PSPaul R. Stokes
Paul R. Stokes
KWKit Wu
Kit Wu
RMRosanna Michalczuk
Rosanna Michalczuk
ABAaf Benecke
Aaf Benecke
ALAnne R. Lingford-Hughes
Anne R. Lingford-Hughes
Pathological gambling (PG) is a behavioural addiction associated with elevated impulsivity and suspected dopamine dysregulation. Reduced striatal dopamine D(2)/D(3) receptor availability has been reported in drug addiction, and may constitute a premorbid vulnerability marker for addictive disorders. The aim of the present study was to assess striatal dopamine D(2)/D(3) receptor availability in PG, and its association with trait impulsivity. Males with PG (n=9) and male healthy controls (n=9) underwent [11C]-raclopride positron emission tomography imaging and completed the UPPS-P impulsivity scale. There was no significant difference between groups in striatal dopamine D(2)/D(3) receptor availability, in contrast to previous reports in drug addiction. However, mood-related impulsivity ('Urgency') was negatively correlated with [11C]-raclopride binding potentials in the PG group. The absence of a group difference in striatal dopamine binding implies a distinction between behavioural addictions and drug addictions. Nevertheless, our data indicate heterogeneity in dopamine receptor availability in disordered gambling, such that individuals with high mood-related impulsivity may show differential benefits from dopamine-based medications.

25 March 2015 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MBMatthijs Bossong
Matthijs Bossong
MMMitul A. Mehta
Mitul A. Mehta
BBBart N. M. van Berckel
Bart N. M. van Berckel
OHOliver D. Howes
Oliver D. Howes
RKRené S. Kahn
René S. Kahn
PSPaul R. A. Stokes
Paul R. A. Stokes

1 October 2009 in NeuroImage
Verified
Journal Article
Closed access
PSPaul R.A. Stokes
Paul R.A. Stokes
MMMitul A. Mehta
Mitul A. Mehta
HCH. Valerie Curran
H. Valerie Curran
GBGerome Breen
Gerome Breen
PGPaul M. Grasby
Paul M. Grasby

1 May 2013 in Neuropharmacology
Verified
Journal Article
Closed access
MMMaria Andreina Mendez
Maria Andreina Mendez
JHJamie Horder
Jamie Horder
JMJim Myers
Jim Myers
SCSuzanne Coghlan
Suzanne Coghlan
PSPaul Stokes
Paul Stokes
DNDavid Nutt
David Nutt